BHCM
CMPX icon

Brevan Howard Capital Management’s Compass Therapeutics CMPX Stock Holding History

Brevan Howard Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.3K Buy
10,202
+2
+0% +$6 ﹤0.01% 2028
2026
Q1 		$54K Sell
10,200
-108,328
-91% -$625K ﹤0.01% 2079
2025
Q4 		$636K Buy
118,528
+72,651
+158% +$335K 0.01% 983
2025
Q3 		$161K Buy
+45,877
New +$145K ﹤0.01% 1799

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brevan Howard Capital Management's CMPX Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Compass Therapeutics (CMPX) stake by 0.02% in Q2 2026, buying an estimated $6 and bringing the position to 10,202 shares worth $22.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2028.

Brevan Howard Capital Management first reported a position in CMPX in Q3 2025 and has held it in 4 quarters since. The position peaked at $636K in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Brevan Howard Capital Management held 10,202 shares of Compass Therapeutics worth $22.3K as of Q2 2026.
  • Brevan Howard Capital Management bought 2 Compass Therapeutics shares in Q2 2026, an estimated $6.
  • Compass Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #2028 holding.
  • Brevan Howard Capital Management first reported a position in Compass Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Compass Therapeutics position peaked at $636K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.